Characterization Of Pharmacokinetics Of 2-((3-(Chloromethyl)Benzoyl)Oxy) Benzoic Acid In Rats By Using Hplc-Dad Method

Caroline, -, Nathania, - and Foe, Kuncoro (2019) Characterization Of Pharmacokinetics Of 2-((3-(Chloromethyl)Benzoyl)Oxy) Benzoic Acid In Rats By Using Hplc-Dad Method. Characterization Of Pharmacokinetics Of 2-((3-(Chloromethyl)Benzoyl)Oxy) Benzoic Acid In Rats By Using Hplc-Dad Method, 11 (5). pp. 279-283. ISSN 0975-7058

	Text (Characterization Of Pharmacokinetics Of 2-((3-(Chloromethyl)Benzoyl)Oxy) Benzoic Acid In Rats By Using Hplc-Dad Method) 3-Characterization_of_pharmacokinetics_.pdf Download (518kB)
Preview	Text (Characterization Of Pharmacokinetics Of 2-((3-(Chloromethyl)Benzoyl)Oxy) Benzoic Acid In Rats By Using Hplc-Dad Method) 3-Characterization_of_hasil cek similarity.pdf Download (1MB) | Preview
Preview	Text (Characterization Of Pharmacokinetics Of 2-((3-(Chloromethyl)Benzoyl)Oxy) Benzoic Acid In Rats By Using Hplc-Dad Method) 3-Characterization_of_hasil cek similarity.pdf Download (1MB) | Preview
	Text (Characterization Of Pharmacokinetics Of 2-((3-(Chloromethyl)Benzoyl)Oxy) Benzoic Acid In Rats By Using Hplc-Dad Method) 3-Characterization_of_pharmacokinetics_Korespondensi_.pdf Download (702kB)

Abstract

Objective: A new compound of salicylic acid derivative, namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3CBB), was synthesized to find a compound exhibiting higher analgesic activity and smaller ulcer irritation than acetylsalicylic acid (ASA). Therefore, this study aimed to investigate the pharmacokinetics of this new compound in rats, following a single dose oral administration of 3CBB (45 mg/kg BW). Methods: Plasma samples of 9 healthy rats were collected before and up to 3 h after its oral administration, following an 18 h fasting period. Plasma concentrations of 3CBB were determined using a validated HPLC-DAD assay. Pharmacokinetic parameters were determined using the compartment model technique. All experiments were carried out in triplicate. Results: The pharmacokinetic parameters of 3CBB obtained were as follows: Tmax= 28.9±1.1 min, Cmax = 0.57±0.02 μg/ml, AUCtotal = 66.3±1.0 μg min/ml, Kel = 0.018±0.002 min-1, and T1/2el = 39.4±3.9 min. The long elimination half-life and low Cmax Conclusion: 3CBB demonstrated a slower onset of action and longer elimination time from the body compared to ASA. Thus this new compound is a potential candidate to be developed as a new drug. indicated that 3CBB was extensively distributed in the deep and very deep tissues. This confirmed the unique and special characteristics of a highly lipophilic compound like 3CBB (log P = 3.73).

Item Type:	Article
Uncontrolled Keywords:	2-((3-(Chloromethyl)benzoyl)oxy)benzoic acid, Pharmacokinetics, Rat, HPLC-DAD
Subjects:	Pharmacy
Divisions:	Journal Publication
Depositing User:	F.X. Hadi
Date Deposited:	19 Apr 2021 03:08
Last Modified:	18 Mar 2024 02:04
URI:	http://repository.ukwms.ac.id/id/eprint/25563

Actions (login required)

View Item